(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.28%) $83.80
(-3.30%) $1.584
(0.09%) $2 344.50
(0.32%) $27.44
(0.78%) $927.70
(0.03%) $0.932
(0.04%) $10.96
(0.00%) $0.799
(-0.01%) $92.16
Live Chart Being Loaded With Signals
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with solid tumors; ATG-527 (Verdinexor) that has completed Phase I evaluation for chronic human viral infections; ATG-019, a dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; ATG-017, an ERK1/2 inhibitor for the treatment of advanced solid tumors and hematologic malignancies; ATG-010 (selinexor), a SINE compound targeting XPO1; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma, as well as ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of solid tumors harboring NFE2L2, STK11, RICTOR, and other specific genetic alterations...
Stats | |
---|---|
Today's Volume | 275 500 |
Average Volume | 359 797 |
Market Cap | 541.10M |
EPS | HKD0 ( 2024-03-28 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -0.840 |
ATR14 | HKD0.0200 (2.33%) |
ANTENGENE-B Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
ANTENGENE-B Financials
Annual | 2023 |
Revenue: | HKD67.31M |
Gross Profit: | HKD55.01M (81.74 %) |
EPS: | HKD-0.940 |
Q4 | 2023 |
Revenue: | HKD-4.71M |
Gross Profit: | HKD-5.07M (107.56 %) |
EPS: | HKD-0.590 |
Q2 | 2023 |
Revenue: | HKD72.02M |
Gross Profit: | HKD59.37M (82.44 %) |
EPS: | HKD-0.360 |
Q4 | 2022 |
Revenue: | HKD106.18M |
Gross Profit: | HKD86.75M (81.70 %) |
EPS: | HKD-0.740 |
Financial Reports:
No articles found.
ANTENGENE-B
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with solid tumors; ATG-527 (Verdinexor) that has completed Phase I evaluation for chronic human viral infections; ATG-019, a dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; ATG-017, an ERK1/2 inhibitor for the treatment of advanced solid tumors and hematologic malignancies; ATG-010 (selinexor), a SINE compound targeting XPO1; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma, as well as ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of solid tumors harboring NFE2L2, STK11, RICTOR, and other specific genetic alterations. Its products in pre-clinical stage include ATG-037 (CD73 inhibitor) for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031 (CD24 antibody); ATG-027 a B7H3/PD-L1 bispecific antibody; ATG-032 (LILRB antibody); and ATG-041, an Axl-Mer inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators